Association of disease duration and PASI response rates at week 12 in patients with moderate-to-severe plaque psoriasis receiving biologics in the real-world psoriasis study of health outcomes (PSoHO)

• Asıl Yazarlar: Andreas Pinter (Yazar), Kilian Eyerich (Yazar), Antonio Costanzo (Yazar), Alyssa Garrelts (Yazar), Christopher Schuster (Yazar), Can Mert (Yazar), Anastasia Lampropoulou (Yazar), Konstantinos Fotiou (Yazar), Julia-Tatjana Maul (Yazar), Kim A. Papp (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

AbstractPurpose Currently, in the treatment of moderate-to-severe psoriasis (PsO) there is a lack of evidence demonstrating optimal biologic treatment response with respect to disease duration. The aim of this post-hoc analysis, using real world data from the Psoriasis Study of Health Outcomes (PSoH...